Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
Authors
Evans, D Gareth RHarkness, E
Howell, Anthony
Wilson, M
Hurley, E
Holmen, M
Tharmaratnam, K
Hagen, A
Lim, Y
Maxwell, A J
Moller, P
Affiliation
Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, ManchesterIssue Date
2016
Metadata
Show full item recordAbstract
The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data from BRCA2 mutation carriers undergoing intensive combined breast screening are scarce.Citation
Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. 2016, 14:8 Hered Cancer Clin PractJournal
Hereditary Cancer in Clinical PracticeDOI
10.1186/s13053-016-0048-3PubMed ID
27087880Type
ArticleLanguage
enISSN
1731-2302ae974a485f413a2113503eed53cd6c53
10.1186/s13053-016-0048-3